急性非淋巴细胞白血病发病率最高，占57.24%。
The ANLL's sick rate was the highest accounting for 57.24 per.
目的探讨死亡受体dr5在急性非淋巴细胞白血病(ANL L)细胞中的表达及其临床意义。
AIM to reveal the expression of death receptor 5 (DR5) in the cells of acute non lymphocyte leukemia (ANLL) and its clinical significance.
目的：探讨急性淋巴细胞白血病(all)与急性非淋巴细胞白血病(ANLL)AT M基因和BRCA2基因杂合性缺失及其相互关系。
Objective: To investigate the loss of heterozygosity (LOH) of ATM gene and BRCA2 gene and explore the relationship between two genes in patients with ALL and ANLL.
本文对29例急性非淋巴细胞白血病(ANLL)患者的血浆血栓调节蛋白(TM)水平进行检测，发现ANLL组血浆TM水平比正常组明显升高。
The plasma concentration of thrombomodulin (TM) were measured in 29 cases of acute non-lymphocytic leukemia (ANLL). Plasma TM level significantly increased in ANLL patients.
Rituxan现在已经被批准用于非霍奇金淋巴瘤、慢性淋巴细胞白血病和风湿性关节炎的治疗。
Rituxan is currently approved as a treatment for non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.
目的：探讨我院急性非淋巴细胞性白血病(ANLL)患者的治疗效果及其预后相关因素。
Objective: to investigated the therapy effect and prognosis related factors in the Acute Non-lymphocytic leukemia (ANLL) patients.
目的：为提高急性非淋巴细胞性白血病(急非淋)的疗效。
Objective To improve the therapeutic effect of acute non-lymphatic leukemia (ANLL).
目的了解多中心协作化疗方案(MCP方案)对急性淋巴细胞白血病(all)和非霍奇金淋巴瘤(NHL)患儿肾脏功能的影响。
Objective to investigate the renal damages in children with acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL) who received the intensive multicenter-protocols (MCP).
目的了解多中心协作化疗方案(MCP方案)对急性淋巴细胞白血病(all)和非霍奇金淋巴瘤(NHL)患儿肾脏功能的影响。
Objective to investigate the renal damages in children with acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL) who received the intensive multicenter-protocols (MCP).
应用推荐